These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1104 related articles for article (PubMed ID: 34534764)

  • 1. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
    Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA
    EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.
    Biron KE; Dickstein DL; Gopaul R; Jefferies WA
    PLoS One; 2011; 6(8):e23789. PubMed ID: 21909359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunization.
    Biron KE; Dickstein DL; Gopaul R; Fenninger F; Jefferies WA
    Sci Rep; 2013; 3():1354. PubMed ID: 23446889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease.
    Kuznetsova E; Schliebs R
    Curr Pharm Des; 2013; 19(38):6749-65. PubMed ID: 23530514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.
    Bell RD; Zlokovic BV
    Acta Neuropathol; 2009 Jul; 118(1):103-13. PubMed ID: 19319544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.
    Van Skike CE; Jahrling JB; Olson AB; Sayre NL; Hussong SA; Ungvari Z; Lechleiter JD; Galvan V
    Am J Physiol Heart Circ Physiol; 2018 Apr; 314(4):H693-H703. PubMed ID: 29351469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow.
    Li H; Guo Q; Inoue T; Polito VA; Tabuchi K; Hammer RE; Pautler RG; Taffet GE; Zheng H
    Mol Neurodegener; 2014 Aug; 9():28. PubMed ID: 25108425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
    Abdallah IM; Al-Shami KM; Yang E; Kaddoumi A
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annexin A1 restores cerebrovascular integrity concomitant with reduced amyloid-β and tau pathology.
    Ries M; Watts H; Mota BC; Lopez MY; Donat CK; Baxan N; Pickering JA; Chau TW; Semmler A; Gurung B; Aleksynas R; Abelleira-Hervas L; Iqbal SJ; Romero-Molina C; Hernandez-Mir G; d'Amati A; Reutelingsperger C; Goldfinger MH; Gentleman SM; Van Leuven F; Solito E; Sastre M
    Brain; 2021 Jun; 144(5):1526-1541. PubMed ID: 34148071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathological changes induced by amyloid-β in Alzheimer's disease].
    Takata K; Kitamura Y; Taniguchi T
    Yakugaku Zasshi; 2011 Jan; 131(1):3-11. PubMed ID: 21212607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrovascular microRNA Expression Profile During Early Development of Alzheimer's Disease in a Mouse Model.
    Chum PP; Hakim MA; Behringer EJ
    J Alzheimers Dis; 2022; 85(1):91-113. PubMed ID: 34776451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease.
    Menet R; Bourassa P; Calon F; ElAli A
    Neurochem Int; 2020 Dec; 141():104881. PubMed ID: 33068684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease.
    Liu CC; Yamazaki Y; Heckman MG; Martens YA; Jia L; Yamazaki A; Diehl NN; Zhao J; Zhao N; DeTure M; Davis MD; Felton LM; Qiao W; Li Y; Li H; Fu Y; Wang N; Wren M; Aikawa T; Holm ML; Oue H; Linares C; Allen M; Carrasquillo MM; Murray ME; Petersen RC; Ertekin-Taner N; Dickson DW; Kanekiyo T; Bu G
    Alzheimers Dement; 2020 Oct; 16(10):1372-1383. PubMed ID: 32827351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease.
    Zhang W; Smith N; Zhou Y; McGee CM; Bartoli M; Fu S; Chen J; Domena JB; Joji A; Burr H; Lv G; Cilingir EK; Bedendo S; Claure ML; Tagliaferro A; Eliezer D; Veliz EA; Zhang F; Wang C; Leblanc RM
    Acta Biomater; 2024 Jul; 183():341-355. PubMed ID: 38849023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Neurovascular Unit Dysfunction in Alzheimer's Disease.
    Soto-Rojas LO; Pacheco-Herrero M; Martínez-Gómez PA; Campa-Córdoba BB; Apátiga-Pérez R; Villegas-Rojas MM; Harrington CR; de la Cruz F; Garcés-Ramírez L; Luna-Muñoz J
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired Amyloid Beta Clearance and Brain Microvascular Dysfunction are Present in the Tg-SwDI Mouse Model of Alzheimer's Disease.
    Rosas-Hernandez H; Cuevas E; Raymick JB; Robinson BL; Sarkar S
    Neuroscience; 2020 Aug; 440():48-55. PubMed ID: 32450297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.
    Mehta DC; Short JL; Hilmer SN; Nicolazzo JA
    Pharm Res; 2015 Mar; 32(3):819-39. PubMed ID: 25319097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.
    Kurz C; Walker L; Rauchmann BS; Perneczky R
    Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12782. PubMed ID: 34823269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mediators of cerebral hypoperfusion and blood-brain barrier leakiness in Alzheimer's disease, vascular dementia and mixed dementia.
    Tayler H; Miners JS; Güzel Ö; MacLachlan R; Love S
    Brain Pathol; 2021 Jul; 31(4):e12935. PubMed ID: 33410232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.